← Leaderboards
Ashraf Z Badros
University Of Maryland Baltimore
$501,616
Attributed
$501,616
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $189K · FY2007–11$200K$150K$100K$50K$0
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$501,616 · 3
By mechanism
R21$344,925 · 1
M01$156,691 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Marcelo B. Sztein$36,733,861
- Vivek Thumbigere-Math$5,274,473
- Irina Mikhailenko$909,276
- France Carrier$2,949,818
- Antonino Passaniti$1,328,420
Others in their field
Top investigators on “Drug Kinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$241,865,009
- Sharon A Nachman · Johns Hopkins University$194,646,762
- Carol Nesel · Westat$147,274,423
- Barbara Driver · Westat, Inc.$103,746,400
- Ronald T Mitsuyasu · University Of California Los Angeles$99,239,507
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,714,869
Research focus
Drug KineticsRelapseOral CavityBaseAdverse EffectsBone ResorptionApoptosisCohortBoneBloodBone DiseasesBone NecrosisAngiogenesis InhibitionBone TurnoverCase-Control StudiesAlveolar BoneCaringBisphosphonateCell-Matrix JunctionCellsCharacteristicsChronicBortezomibBinding (Molecular Function)
Grant awards (4)
Role of Salivary Bisphosphonates in Osteonecrosis of the Jaw in Myeloma Patients$155,925
R21 · FY2011 · DE · contact PI
Role of Salivary Bisphosphonates in Osteonecrosis of the Jaw in Myeloma Patients$189,000
R21 · FY2010 · DE · contact PI
CLINICAL TRIAL: STUDY OF SAHA WITH BORTEZOMIB IN RELAPSED & REFRACTORY MULTIPLE$95,668
M01 · FY2008 · RR · contact PI
0514 GCC: A PHASE 1 STUDY OF SAHA IN COMBINATION WITH BORTEZOMIB IN RELAPSED$61,023
M01 · FY2007 · RR · contact PI